semaglutide .25 mg Wegovy® 0.25 / 0.5 mL Injection 4 25 mg semaglutide in syringe

3.4 Appetite regulation and weight management Similar to animal studies with deletion of the GIPR gene that exhibit protection toward obesity (53), early genome-wide association studies (GWAS) in humans have revealed the GIPR gene to be associated with BMI (103)

Hunger often improves as treatment progresses and habits align with the medications effects

Patients with certain genetic predispositions may achieve target weight loss on lower doses, reducing both side effect severity and the likelihood of dose-related mistakes

Typically, insurance plans will want to ensure that you are using the drug for an FDA-approved use, such as Zepbound for moderate to severe sleep apnea in adults with obesity